On March 18, 2024, Outlook Therapeutics, Inc. closed the transaction. The company has issued 8,571,423 shares and warrants to purchase an aggregate of 12,857,133 shares of common stock at a price of $7 per share for the gross proceeds of $59,999,961.The warrants have an exercise price of $7.70 per share of common stock and will expire on March 18, 2029. The shares and warrants issued are in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and/or Rule 506 promulgated under the Securities Act.

The company has received $60,000,000 from 21 investors pursuant to exemption provided under Regulation D.